CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical study for its pipeline candidate SYS6023. The study will initially focus on patients with general advanced solid tumors. This antibody drug conjugate (ADC) had previously been given the green light for trials in China in March this year.
SYS6023 is designed as an ADC that targets tumor-specific surface receptors. It has the capability to enter tumor cells through endocytosis and release toxins, thereby achieving the effect of killing tumor cells. Pre-clinical studies have demonstrated that this molecule can elicit positive anti-tumor effects across multiple types of tumors.- Flcube.com
